Table 1. Summary statistics of relative Gal-3 and relative PSA levels.
| Group | Relative variable |
N | Mean | Standard deviation | Median | Minimum | Maximum |
|---|---|---|---|---|---|---|---|
| All men | PSA | 95 | 5111 | 31078 | 2.2 | 0.0 | 289375 |
| Gal-3 | 95 | 344.8 | 1500 | 1.3 | 0.3 | 8671 | |
| Healthy controls | PSA | 19 | 244.3 | 503.1 | 0.8 | 0.1 | 1667 |
| Gal-3 | 19 | 3.0 | 4.7 | 1.4 | 0.4 | 17.2 | |
| Newly diagnosed | PSA | 19 | 1230 | 1810 | 7.9 | 0.1 | 5542 |
| Gal-3 | 19 | 327.4 | 1420 | 0.9 | 0.3 | 6192 | |
| No recurrence | PSA | 19 | 3.3 | 7.8 | 0.0 | 0.0 | 20.8 |
| Gal-3 | 19 | 225.5 | 976.6 | 0.8 | 0.4 | 4258 | |
| Rising PSA | PSA | 19 | 395.1 | 984.2 | 3.2 | 0.1 | 3333 |
| Gal-3 | 19 | 391.5 | 1698 | 1.3 | 0.7 | 7404 | |
| Metastasis | PSA | 19 | 23682 | 67701 | 14.4 | 0.0 | 289375 |
| Gal-3 | 19 | 776.5 | 2357 | 2.1 | 0.3 | 8671 | |
Gal-3 and PSA concentrations were divided by their respective autoantibody levels, and the values were referred to as relative Gal-3 and relative PSA. Descriptive statistics of the relative Gal-3 and relative PSA level are shown separately for each clinical classification.